Rhythm’s ColoSTAT® Faces Adoption Challenge Despite 4Cyte Partnership

Strategic Partnership to Broaden ColoSTAT® Access

Rhythm Biosciences Ltd (ASX, RHY) has taken a significant step in commercialising its blood-based colorectal cancer diagnostic test, ColoSTAT®, by entering into a non-exclusive distribution service agreement with 4Cyte Pathology. This partnership leverages 4Cyte’s extensive network of more than 1,000 patient collection centres across New South Wales, Victoria, and Queensland, integrating ColoSTAT® into routine clinical workflows.

ColoSTAT® is designed as an alternative screening pathway for individuals who are unable or unwilling to complete traditional faecal-based tests. By measuring five specific protein biomarkers, the test offers a blood-based method to assess the likelihood of colorectal cancer, a disease that remains the second leading cause of cancer deaths globally.

Operational and Commercial Benefits

Under the agreement, 4Cyte will facilitate ordering through its clinical systems, support patient sample collection via its phlebotomy network, and coordinate sample transport to Rhythm’s ISO 15189-accredited laboratory in Parkville, Victoria. Results will be delivered back to healthcare practitioners through 4Cyte’s established reporting channels.

Importantly, Rhythm will perform all testing and invoice patients directly, with no upfront payments or minimum volume commitments required from either party. This variable cost structure aligns Rhythm’s expenses with actual testing volumes, providing capital efficiency during the early commercialisation phase.

Implications for Market Adoption

The partnership addresses a critical barrier to adoption by embedding ColoSTAT® into familiar clinical ordering systems, making it easier for healthcare practitioners to request the test. With colorectal cancer screening participation in Australia still below 50%, this expanded access could play a pivotal role in increasing screening rates and early detection.

While the agreement does not guarantee revenue, it offers Rhythm a scalable platform to grow its market presence without the need for significant capital investment. The company will provide updates on testing volumes and commercial progress as the integration and rollout proceed.

Looking Ahead

Rhythm and 4Cyte are now focused on completing technical integration and establishing operational workflows. The timing of the commercial rollout will depend on these milestones, with further updates expected as the partnership develops.